Catalyst Wire Dossier Catalyst Wire Dossier

Cosentyx

secukinumab · Novartis Pharmaceuticals Corporation
Drug timelines are a Plus or Pro feature.

96 regulatory and trial events tracked for Cosentyx, covering 2015-01-21 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome [Phase 4]

See pricing